ArticleInfection and immunity2014
Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium falciparum and Plasmodium vivax malaria.
Article in Infection and immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Molecular mechanisms involved inFrontiers in microbiology · 2026Review
- Thioester-Containing Protein TEP27 inInternational journal of molecular sciences · 2025Article
- Mosquito-based transmission-blocking vaccine candidates for malaria: progress, challenges, and innovations.Molecular biology reports · 2025Review
- mosGILT antibodies interfere with Plasmodium sporogony in Anopheles gambiae.Nature communications · 2025Article
- Multi-locus investigation of Anopheles-mediated selective pressure on Plasmodium falciparum in Africa.Parasites & vectors · 2024Article
- Multi-locus investigation of Anopheles-mediated selective pressure on Plasmodium falciparum in Africa.Research square · 2024Article
- Article
- Targeting plasmodium α-tubulin-1 to block malaria transmission to mosquitoes.Frontiers in cellular and infection microbiology · 2023Article
- Review
- Quantifying Reductions inFrontiers in immunology · 2022Article
- Novel malaria vaccines.Human vaccines & immunotherapeutics · 2021Article
- Evaluation of two Plasmodium vivax sexual stage antigens as transmission-blocking vaccine candidates.Parasites & vectors · 2021Article
- Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone.Malaria journal · 2021Article
- Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen.NPJ vaccines · 2021Article
- Probing theBiomedicines · 2021Article
- Targeting Gametocytes of the Malaria ParasitePathogens (Basel, Switzerland) · 2021Review
- Progress towards the development of aExpert review of vaccines · 2021Review
- Immunopotentiation by Lymph-Node Targeting of a Malaria Transmission-Blocking Nanovaccine.Frontiers in immunology · 2021Article
- Identification of Novel Malaria Transmission-Blocking Vaccine Candidates.Frontiers in cellular and infection microbiology · 2021Review
- Analysis of blood-induced Anopheles gambiae midgut proteins and sexual stage Plasmodium falciparum interaction reveals mosquito genes important for malaria transmission.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Malaria transmission-blocking vaccines (TBVs) represent a promising approach for the elimination and eradication of this disease. AnAPN1 is a lead TBV candidate that targets a surface antigen on the midgut of the obligate vector of the Plasmodium parasite, the Anopheles mosquito. In this study, we demonstrated that antibodies targeting AnAPN1 block transmission of Plasmodium falciparum and Plasmodium vivax across distantly related anopheline species in countries to which malaria is endemic. Using a biochemical and immunological approach, we determined that the mechanism of action for this phenomenon stems from antibody recognition of a single protective epitope on AnAPN1, which we found to be immunogenic in murine and nonhuman primate models and highly conserved among anophelines. These data indicate that AnAPN1 meets the established target product profile for TBVs and suggest a potential key role for an AnAPN1-based panmalaria TBV in the effort to eradicate malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.